NFA
AEGR

Nationwide Fund Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Nationwide Fund Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-16,333
Closed -$60K – 3355
2016
Q1 		$60K Hold
16,333
– – ﹤0.01% 2953
2015
Q4 		$165K Hold
16,333
– – ﹤0.01% 2642
2015
Q3 		$222K Hold
16,333
– – ﹤0.01% 2509
2015
Q2 		$310K Sell
16,333
-5,311
-25% -$115K ﹤0.01% 2490
2015
Q1 		$566K Sell
21,644
-975
-4% -$24.8K ﹤0.01% 2177
2014
Q4 		$474K Sell
22,619
-206
-0.9% -$5.19K ﹤0.01% 2212
2014
Q3 		$762K Sell
22,825
-20,658
-48% -$641K ﹤0.01% 1966
2014
Q2 		$1.4M Buy
43,483
+21,229
+95% +$790K 0.01% 1689
2014
Q1 		$1.03M Sell
22,254
-18,339
-45% -$1.08M ﹤0.01% 1719
2013
Q4 		$2.88M Sell
40,593
-42,688
-51% -$3.26M 0.01% 1260
2013
Q3 		$7.14M Buy
83,281
+32,529
+64% +$2.76M 0.03% 701
2013
Q2 		$3.21M Buy
+50,752
New +$2.69M 0.02% 1048

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nationwide Fund Advisors's AEGR Position: Q2 2016 in Review

Nationwide Fund Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 16,333 shares — an estimated $60K sold.

Nationwide Fund Advisors first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $7.14M in Q3 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • Nationwide Fund Advisors reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Nationwide Fund Advisors sold 16,333 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $60K.
  • Nationwide Fund Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Nationwide Fund Advisors's Aegerion Pharmaceuticals position peaked at $7.14M in Q3 2013.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Nationwide Fund Advisors's 13F filing for Q2 2016, filed 9 Aug 2016.